|
Market Closed -
Nasdaq
16:00:00 2026-10-19 EDT
|
5-day change | 1st Jan Change | ||
| 0.3460 USD | -11.30% |
|
-42.81% | -95.30% |
| 08-31 | Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis | CI |
| 08-29 | Karyopharm Therapeutics Inc. - Special Call |
Company Valuation: Karyopharm Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 485.8 | 384.9 | 99.07 | 85.34 | 134.8 | 8.848 | - | - |
| Change | - | -20.76% | -74.26% | -13.86% | 57.91% | -93.43% | - | - |
| Enterprise Value (EV) | 426.4 | 277.1 | 99.07 | 85.34 | 134.8 | 8.848 | 8.848 | 8.848 |
| Change | - | -35.03% | -64.24% | -13.86% | 57.91% | -93.43% | 0% | 0% |
| P/E | -3.9x | -1.68x | -0.69x | -1.07x | -0.41x | -0.07x | -0.14x | -0.22x |
| PBR | -6.07x | -16.7x | - | - | - | - | - | - |
| PEG | - | -0.1x | 0x | 0x | -0x | 0x | 0x | 0x |
| Capitalization / Revenue | 2.32x | 2.45x | 0.68x | 0.59x | 0.92x | 0.07x | 0.05x | 0.03x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.07x | 0.05x | 0.03x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.09x | -0.15x | -3.34x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -24.75 | -30.3 | -18.75 | -9.45 | -17.93 | -4.7 | -2.387 | -1.575 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 209.8 | 157.1 | 146 | 145.2 | 146.1 | 135.6 | 173.6 | 332.3 |
| EBITDA | -97.48 | -141.6 | - | - | - | - | - | - |
| EBIT 1 | -98.27 | -142.2 | -129.5 | -119.4 | -90.71 | -98.75 | -60.21 | -2.649 |
| Net income 1 | -124.1 | -165.3 | -143.1 | -76.42 | -196 | -160.2 | -114.9 | -85.6 |
| Net Debt | -59.32 | -107.9 | - | - | - | - | - | - |
| Reference price 2 | 96.4500 | 51.0000 | 12.9750 | 10.1445 | 7.3600 | 0.3460 | 0.3460 | 0.3460 |
| Nbr of stocks (in thousands) | 5,037 | 7,548 | 7,636 | 8,413 | 18,310 | 22,681 | - | - |
| Announcement Date | 2/8/22 | 2/15/23 | 2/29/24 | 2/19/25 | 2/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.08x | - | - | - | 8.85M | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 26.14x | 6.95x | 18.39x | 2.15% | 394.09B | |
| Weighted average by Cap. | 34.72x | 8.20x | 20.04x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- KPTI Stock
- Valuation Karyopharm Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
